RIO DE JANEIRO--(BUSINESS WIRE)-- Cryopraxis established in 2001 as the pioneer private umbilical cord blood bank in Brazil will be present at Bio 2012 in Boston. Eduardo Cruz, chairman of the board, will be a speaker at the Brazilian break-out session speaking about The Brazilian Biotechnology Sector and showing the results of the company's commitment to R&D. Cryopraxis has already collected and processed more than 25000 cord blood units (CBU) and is actively involved in several R&D projects in Brazil and abroad. A spin-off of Cryopraxis, Cellpraxis, has recently finished one of the world's first cell therapy project clinical trials in Brazil: ReACT. ReACT is a stem cell formulation. This regenerative medicine pioneer product aims on treating an orphan disease condition called refractory angina. Refractory angina patients suffer from untreatable severe chest pain and the results of the clinical trial in a 5 years follow up proved ReACT to positively interfere in the course of the pathology. Most of the individuals treated experienced relief in pain and better quality of life. ReACT will be presented at Bio2012 as an example of Brazil's dynamic biotechnology research. Cryopraxis is accredited by the American Association of Blood Bank since 2009. According to Tatiana … Continue reading →

2011 saw the stem cell market earn revenues of $148.4 million in 2011 and this is forecast to reach $322 million by 2017. The segments covered include: bio-imaging and microscopy, cell biology tools, immunochemical, molecular biology tools, and protein biochemistry tools. The US is one of the major stem cell markets in the world, and the country has been witnessing a significant level of positive growth over the past few years. The US stem cell market was estimated to reach around $830 Million in 2010, up from $500 Million in 2009. This market growth can be attributed to a number of supporting factors, such as huge investment, strong demand, and rising disease incidences. Forecasters have predicted that these factors will lead to the US stem cell market generating revenues of $3 billion by 2013. A key step forward for the market has been the stem cell regulations in a few countries allowing the use of certain cell lines. In some countries such as France, for instance, stem cell regulations are being renewed for the procurement and use of stem cells. Standardised research guidelines are needed to control and encourage the development of gene therapy and stem cell treatments. Regenerative medicine … Continue reading →

BYRON, MN--It's a dream for many in the medical field, to use a person's own stem cells to help them heal. And it's a reality already happening in our area. But it's not humans who are being treated. In this case, dogs are the ones being treated. Animal Stem Cell Regenerative Therapy has been performed a few thousand times now across the U.S. Doctors harvest stem cells and re-enter them where the animal is having problems. Both Marley and Vinnie have bad ligaments in their legs, and like many dogs suffering from arthritis, they are subject to monthly doses of expensive drugs. That is until today. Dr. Garren Kelly, D.V.M. at Meadow View Veterinary Clinic just outside Rochester says, "If you'd of asked me 5 years ago if I would be doing anything like this, I would have said no. But then as soon as I saw it i'm like 'Yeah that's for me'. I kind of like staying on the cutting edge of technology and surgeries". The two are undergoing a first of its kind surgery in minnesota, using regenerative stem cells. Blood is taken from the dogs, as well as fat tissue. Then stem cells are separated out … Continue reading →

ROCKVILLE, Md., June 19, 2012 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient to receive stem cell transplantation in both regions of the spinal cord has been treated in the ongoing Phase I trial of its spinal cord neural stem cells in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). This is also the 16th patient to be treated in the trial altogether and the first patient returning to the trial for a second treatment. In this treatment, the patient received five injections in the cervical (upper back) region of the spinal cord, in addition to the ten he received previously in the lumbar (lower back) region of the spine, for a total of 15 injections. This is the highest number of injections in the trial so far. Patient 16 is also the first patient in the world to receive stem cell transplants in both the lumbar and cervical regions of the spinal cord in an FDA-approved trial. Two additional previously-treated patients are expected to return to the trial this summer in this cohort, provided they continue to meet the inclusion requirements. The trial is taking place at Emory University Hospital in Atlanta, Georgia. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) … Continue reading →

Public release date: 19-Jun-2012 [ | E-mail | Share ] Contact: Myles Gough myles.gough@unsw.edu.au 61-029-385-1933 University of New South Wales With advances in nanotechnology, the future of medicine is taking shape on the nano-scale and making possible healthcare solutions once confined to the realm of science fiction. From microscopic robots that could soon be swimming around our bloodstream repairing cells and diagnosing diseases, to drugs with improved therapeutic properties that can selectively target affected regions of the body with cellular precision without damaging surrounding tissue. The Australian Centre for Nanomedicine at the University of New South Wales is at the forefront of this exciting new discipline and will host the third International Nanomedicine Conference from 2 4 July in Sydney. The conference will bring together world-leading academics and clinicians to highlight important research into targeted drug delivery systems, diagnostics and imaging, and regenerative medicine, all enabled by nanomedicine. One nanometre is equivalent to one-billionth of a metre and is roughly 60,000 times thinner than a human hair, or the size of a single strand of DNA. By exploiting the novel biological, chemical and physical properties of materials at this scale, researchers can build devices and systems that improve disease detection … Continue reading →